{"log_id": 8949833703750444539, "direction": 0, "words_result_num": 54, "words_result": [{"probability": {"variance": 0.023442, "average": 0.733191, "min": 0.550565}, "location": {"width": 259, "top": 221, "height": 28, "left": 243}, "words": "对盐酸维敏的病"}, {"probability": {"variance": 3e-06, "average": 0.996849, "min": 0.994753}, "location": {"width": 107, "top": 255, "height": 26, "left": 172}, "words": "注意事项"}, {"probability": {"variance": 0.047418, "average": 0.784747, "min": 0.38358}, "location": {"width": 480, "top": 271, "height": 38, "left": 243}, "words": "必须整削量以达到钵化疗。必须食翻商射服翔"}, {"probability": {"variance": 0.030803, "average": 0.850761, "min": 0.456616}, "location": {"width": 838, "top": 291, "height": 47, "left": 244}, "words": "心力衰竭:维拉米的负性肌力作用可因其碱轻后负蔺(降低环维管阻力面代偿诤效应"}, {"probability": {"variance": 0.032463, "average": 0.883128, "min": 0.422126}, "location": {"width": 916, "top": 318, "height": 51, "left": 165}, "words": "损害心室功能。但是严重左心室期能不毛肺楔压大于20mg或射血分数小于30%、申重度心力衰"}, {"probability": {"variance": 0.018464, "average": 0.934929, "min": 0.4709}, "location": {"width": 916, "top": 347, "height": 48, "left": 166}, "words": "病人、巴接受受体阻滞剂治疗的任何程度的心室功能障碍的病人,避兔使用维拉帕米:必须使用维拉"}, {"probability": {"variance": 0.013472, "average": 0.932958, "min": 0.603409}, "location": {"width": 674, "top": 381, "height": 42, "left": 166}, "words": "米的轻度心功能不全的病人,治疗之前露已有洋地黄类或利尿剂控制临床症状"}, {"probability": {"variance": 0.016599, "average": 0.941617, "min": 0.39714}, "location": {"width": 831, "top": 403, "height": 45, "left": 252}, "words": "激综合征:维拉帕米会加速房室旁路前向传导。房室路通道合并心房扑动或心房颤动病人静"}, {"probability": {"variance": 0.002915, "average": 0.980181, "min": 0.699139}, "location": {"width": 918, "top": 430, "height": 48, "left": 166}, "words": "脉用维拉帕米治疗,会通过加速房室旁路的前向传导,引起心室率加快,甚至诱发心室颤动。虽然口服维"}, {"probability": {"variance": 0.013066, "average": 0.959001, "min": 0.425413}, "location": {"width": 693, "top": 462, "height": 41, "left": 169}, "words": "拉帕米未见上述报道,但这种人接受口服维拉帕米可能有危险,因此禁止使用"}, {"probability": {"variance": 0.005991, "average": 0.971894, "min": 0.573686}, "location": {"width": 836, "top": 483, "height": 46, "left": 247}, "words": "传导阻滞:维拉帕米可能导致房室结和窦房结传导阻滞:与血浆浓度增高相关,尤其是在治疗早"}, {"probability": {"variance": 0.014608, "average": 0.953578, "min": 0.384289}, "location": {"width": 911, "top": 511, "height": 48, "left": 169}, "words": "期的增量期。引起1度房室阻滞、一过性窦性心动过缓:有时伴有结性逸搏。高度房室传导阻滞不常见(0.8"}, {"probability": {"variance": 0.016953, "average": 0.9351, "min": 0.463866}, "location": {"width": 804, "top": 540, "height": 47, "left": 169}, "words": "当出现显著的1度房室传导阻滞或逐渐发展成I或III度房室传导阻滞时,需要减量或停药"}, {"probability": {"variance": 0.015972, "average": 0.943605, "min": 0.373581}, "location": {"width": 872, "top": 564, "height": 48, "left": 216}, "words": "5.肝功能损害:因维拉帕米在内广泛代谢,肝功能损害的病人慎用维拉帕米。严重肝功能不全"}, {"probability": {"variance": 7.9e-05, "average": 0.995621, "min": 0.95044}, "location": {"width": 680, "top": 598, "height": 42, "left": 170}, "words": "维拉帕米的清除半衰期延长至14~16小时,该类病人只需服用正常剂量的30%"}, {"probability": {"variance": 0.018195, "average": 0.950354, "min": 0.398366}, "location": {"width": 868, "top": 619, "height": 48, "left": 217}, "words": "6.肾功能损害:肾功能损害的病人慎用维拉帕米。密切观察PR间期的异常延长或其它中毒症状。"}, {"probability": {"variance": 0.000731, "average": 0.976615, "min": 0.920924}, "location": {"width": 221, "top": 664, "height": 32, "left": 170}, "words": "液透析不能清除维拉帕米"}, {"probability": {"variance": 0.000454, "average": 0.994046, "min": 0.858846}, "location": {"width": 857, "top": 675, "height": 47, "left": 221}, "words": "7.神经肌肉传导减弱:有报道维拉帕米减弱肌肉萎缩病人的神经肌肉传导,该类病人可能需要减量"}, {"probability": {"variance": 0.000604, "average": 0.98957, "min": 0.878494}, "location": {"width": 867, "top": 703, "height": 46, "left": 220}, "words": "8.血清钙:维拉帕米不改变血清钙浓度,但也有高于正常范围的血钙水平可能影响维拉帕米疗效的"}, {"probability": {"variance": 2e-05, "average": 0.994203, "min": 0.989716}, "location": {"width": 43, "top": 751, "height": 25, "left": 173}, "words": "报道"}, {"probability": {"variance": 0.015134, "average": 0.952283, "min": 0.440601}, "location": {"width": 646, "top": 761, "height": 43, "left": 221}, "words": "9.因维拉帕米可引起氨基转移酶增高,为慎重起见,接受维拉帕米治疗的"}, {"probability": {"variance": 0.049566, "average": 0.824649, "min": 0.510495}, "location": {"width": 192, "top": 750, "height": 51, "left": 872}, "words": "肝功能"}, {"probability": {"variance": 4e-06, "average": 0.997647, "min": 0.993598}, "location": {"width": 226, "top": 800, "height": 31, "left": 181}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.007241, "average": 0.972068, "min": 0.481446}, "location": {"width": 876, "top": 810, "height": 49, "left": 212}, "words": "维拉帕米可通过胎盘。在孕妇中使用应权衡利弊。维拉帕米可分泌乳汁,服维拉采期间应中断"}, {"probability": {"variance": 1e-06, "average": 0.998312, "min": 0.99709}, "location": {"width": 40, "top": 861, "height": 24, "left": 175}, "words": "哺乳"}, {"probability": {"variance": 2.9e-05, "average": 0.995912, "min": 0.984649}, "location": {"width": 109, "top": 885, "height": 28, "left": 182}, "words": "【儿童用药】"}, {"probability": {"variance": 0.000178, "average": 0.994687, "min": 0.942222}, "location": {"width": 347, "top": 904, "height": 38, "left": 214}, "words": "18岁以下儿童的安全性和疗效尚未确定"}, {"probability": {"variance": 2e-06, "average": 0.998301, "min": 0.995099}, "location": {"width": 106, "top": 943, "height": 24, "left": 185}, "words": "【老年用药】"}, {"probability": {"variance": 2.6e-05, "average": 0.996711, "min": 0.977482}, "location": {"width": 875, "top": 946, "height": 51, "left": 217}, "words": "老年病人的清除半衰期可能延长,并且必须考虑到老年人发生肝或肾功能不全更为常见。一般地,老"}, {"probability": {"variance": 7e-06, "average": 0.998044, "min": 0.992022}, "location": {"width": 220, "top": 994, "height": 30, "left": 177}, "words": "年人应用较低的起始剂量"}, {"probability": {"variance": 1.1e-05, "average": 0.997979, "min": 0.989505}, "location": {"width": 146, "top": 1023, "height": 26, "left": 185}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.001667, "average": 0.988395, "min": 0.735686}, "location": {"width": 877, "top": 1029, "height": 50, "left": 215}, "words": "1环磷酰胺、长春新碱、甲基苄肼、强的松、长春碱酰胺、阿霉素、顺铂等细胞毒性药物减少维拉帕"}, {"probability": {"variance": 1.4e-05, "average": 0.99677, "min": 0.99069}, "location": {"width": 77, "top": 1080, "height": 24, "left": 179}, "words": "米的吸收"}, {"probability": {"variance": 0.001071, "average": 0.983992, "min": 0.868263}, "location": {"width": 287, "top": 1097, "height": 36, "left": 215}, "words": "2.苯巴比妥增加维拉帕米的清除"}, {"probability": {"variance": 0.002115, "average": 0.985631, "min": 0.78096}, "location": {"width": 405, "top": 1122, "height": 38, "left": 216}, "words": "3.雷米封显著降低口服维拉帕米的生物利用度"}, {"probability": {"variance": 0.00069, "average": 0.989517, "min": 0.879759}, "location": {"width": 383, "top": 1150, "height": 38, "left": 217}, "words": "4.西咪替丁可能提高维拉帕米的生物利用度"}, {"probability": {"variance": 0.004216, "average": 0.985207, "min": 0.618192}, "location": {"width": 700, "top": 1170, "height": 44, "left": 217}, "words": "5.维拉帕米抑制乙醇的消除,导致血中乙醇浓度增加,可能延长酒精的毒性作用"}, {"probability": {"variance": 0.006128, "average": 0.977444, "min": 0.619781}, "location": {"width": 728, "top": 1196, "height": 47, "left": 216}, "words": "6.与B受体阻滞剂联合使用,可能增强对房室传导、心率和/或心脏收缩的抑制作用"}, {"probability": {"variance": 0.001743, "average": 0.983844, "min": 0.793045}, "location": {"width": 876, "top": 1219, "height": 51, "left": 219}, "words": "7.长期服用维拉帕米,使地高辛血药浓度增加50%~75%。维拉帕米明显影响肝硬化病人地高辛的药代"}, {"probability": {"variance": 0.00037, "average": 0.994578, "min": 0.864057}, "location": {"width": 910, "top": 1248, "height": 51, "left": 182}, "words": "动力学,使地高辛的总清除率和肾外清除率分别减少27%和29%。因此服用维拉帕米时,须减少地高辛和洋"}, {"probability": {"variance": 2e-06, "average": 0.998444, "min": 0.995425}, "location": {"width": 103, "top": 1300, "height": 26, "left": 182}, "words": "地黄的剂量"}, {"probability": {"variance": 0.00102, "average": 0.98556, "min": 0.839829}, "location": {"width": 877, "top": 1301, "height": 58, "left": 220}, "words": "8与血管扩张剂、血管紧张素转换酶抑制剂、利尿剂等抗高血压药合用时,降压作应适当监"}, {"probability": {"variance": 8e-06, "average": 0.997513, "min": 0.990521}, "location": {"width": 202, "top": 1353, "height": 29, "left": 183}, "words": "测联合降压治疗的病人"}, {"probability": {"variance": 0, "average": 0.840782, "min": 0.840782}, "location": {"width": 158, "top": 1336, "height": 38, "left": 912}, "words": "發"}, {"probability": {"variance": 0.000839, "average": 0.987236, "min": 0.87985}, "location": {"width": 307, "top": 1374, "height": 36, "left": 220}, "words": "9.与胺碘酮合用可能增加心脏毒性"}, {"probability": {"variance": 0.001028, "average": 0.987732, "min": 0.825272}, "location": {"width": 588, "top": 1392, "height": 47, "left": 223}, "words": "1.维拉帕米与氟卡胺合用,可使负性肌力作用叠加,房室传导延长"}, {"probability": {"variance": 0.01244, "average": 0.951339, "min": 0.471501}, "location": {"width": 488, "top": 1424, "height": 42, "left": 226}, "words": "11.维拉帕米可增加卡马西平、环孢素、茶碱的血药浓度"}, {"probability": {"variance": 0.001021, "average": 0.989818, "min": 0.840338}, "location": {"width": 484, "top": 1452, "height": 41, "left": 226}, "words": "2.有报道维拉帕米增加病人对锂的敏感性(神经毒性)"}, {"probability": {"variance": 0.009121, "average": 0.964143, "min": 0.502736}, "location": {"width": 755, "top": 1470, "height": 52, "left": 228}, "words": "3.动物实验提示吸入性麻醉剂与维拉帕米同时使用时,需仔细调整两药剂量,避免过度"}, {"probability": {"variance": 0.003204, "average": 0.984011, "min": 0.694759}, "location": {"width": 543, "top": 1506, "height": 42, "left": 220}, "words": "4.服用维拉帕米前48小时内或服用后24小时不得服用丙吡胺"}, {"probability": {"variance": 1e-06, "average": 0.998485, "min": 0.996461}, "location": {"width": 108, "top": 1548, "height": 27, "left": 194}, "words": "【药物过量】"}, {"probability": {"variance": 0.000326, "average": 0.994986, "min": 0.878505}, "location": {"width": 876, "top": 1556, "height": 47, "left": 226}, "words": "服用维拉帕米过量的主要表现为低血压和心动过缓(如房室分离、高度房室传导阻滞、心脏停搏)、精"}, {"probability": {"variance": 0.000153, "average": 0.9953, "min": 0.932535}, "location": {"width": 593, "top": 1588, "height": 44, "left": 190}, "words": "神错乱、昏迷、恶心、呕吐、肾功能不全、代谢性酸中毒和高血糖等"}, {"probability": {"variance": 0.000773, "average": 0.992686, "min": 0.814025}, "location": {"width": 878, "top": 1609, "height": 50, "left": 220}, "words": "对症治疗包括应用阿托品、异丙肾上腺素和心脏起搏治疗及静脉输液、血管收缩剂、钙溶液(如10%的"}], "language": 3}